KR960009410B1 - Sustained release etodolac - Google Patents

Sustained release etodolac Download PDF

Info

Publication number
KR960009410B1
KR960009410B1 KR88012298A KR880012298A KR960009410B1 KR 960009410 B1 KR960009410 B1 KR 960009410B1 KR 88012298 A KR88012298 A KR 88012298A KR 880012298 A KR880012298 A KR 880012298A KR 960009410 B1 KR960009410 B1 KR 960009410B1
Authority
KR
South Korea
Prior art keywords
etodolac
sustained release
weight
content
release etodolac
Prior art date
Application number
KR88012298A
Other languages
English (en)
Other versions
KR890004686A (ko
Inventor
John Joseph Michelucci
Deborah Marie Sherman
Richard Jay Deneale
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of KR890004686A publication Critical patent/KR890004686A/ko
Application granted granted Critical
Publication of KR960009410B1 publication Critical patent/KR960009410B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
KR88012298A 1987-09-24 1988-09-23 Sustained release etodolac KR960009410B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10050187A 1987-09-24 1987-09-24
US100,501 1987-09-24

Publications (2)

Publication Number Publication Date
KR890004686A KR890004686A (ko) 1989-05-09
KR960009410B1 true KR960009410B1 (en) 1996-07-19

Family

ID=22280080

Family Applications (1)

Application Number Title Priority Date Filing Date
KR88012298A KR960009410B1 (en) 1987-09-24 1988-09-23 Sustained release etodolac

Country Status (21)

Country Link
US (1) US4966768A (ko)
EP (1) EP0309157B1 (ko)
JP (1) JP2879061B2 (ko)
KR (1) KR960009410B1 (ko)
AT (1) ATE62132T1 (ko)
AU (1) AU613663B2 (ko)
CA (1) CA1318600C (ko)
DE (1) DE3862272D1 (ko)
DK (1) DK168421B1 (ko)
ES (1) ES2021838B3 (ko)
FI (1) FI89005C (ko)
GB (1) GB2209940B (ko)
GR (1) GR3001739T3 (ko)
HK (1) HK41994A (ko)
HU (1) HU200920B (ko)
IE (1) IE60311B1 (ko)
IL (1) IL87757A (ko)
MX (1) MX171463B (ko)
PH (1) PH26146A (ko)
PT (1) PT88564B (ko)
ZA (1) ZA887162B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
IN182040B (ko) * 1995-06-13 1998-12-12 American Home Prod
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US20060068001A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
EP1137403B1 (en) 1998-12-11 2009-03-11 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
IN190974B (ko) * 1999-09-10 2003-09-06 Ranbaxy Lab Ltd
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2003026687A1 (en) * 2001-09-28 2003-04-03 Nutraceutix, Inc. Delivery system for biological component
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
IL161491A0 (en) * 2001-11-07 2004-09-27 Synthon Bv Tamsulosin tablets
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003202550A1 (en) * 2002-01-09 2003-07-24 Ucb, S.A. Pharmaceutical formulations with modified release
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003295336A1 (en) * 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
PL2010158T3 (pl) * 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
TR200908308A1 (tr) 2010-01-18 2011-08-22 Turgut İlaçlari A.Ş. Etodolak içeren sürekli salım tablet formulasyonu
CN102485215B (zh) * 2010-12-03 2013-05-15 沈阳药科大学 依托度酸定时释药微丸制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939178A (en) * 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate

Also Published As

Publication number Publication date
ZA887162B (en) 1990-05-30
FI884245A (fi) 1989-03-25
EP0309157A1 (en) 1989-03-29
ES2021838B3 (es) 1991-11-16
HUT50631A (en) 1990-03-28
PT88564A (pt) 1988-10-01
GB8821749D0 (en) 1988-10-19
DE3862272D1 (de) 1991-05-08
DK168421B1 (da) 1994-03-28
JP2879061B2 (ja) 1999-04-05
FI884245A0 (fi) 1988-09-15
HU200920B (en) 1990-09-28
IL87757A (en) 1992-06-21
MX171463B (es) 1993-10-28
PT88564B (pt) 1992-11-30
CA1318600C (en) 1993-06-01
AU613663B2 (en) 1991-08-08
DK531088A (da) 1989-03-25
US4966768A (en) 1990-10-30
IL87757A0 (en) 1989-02-28
ATE62132T1 (de) 1991-04-15
GR3001739T3 (en) 1992-11-23
HK41994A (en) 1994-05-06
PH26146A (en) 1992-03-18
GB2209940A (en) 1989-06-01
KR890004686A (ko) 1989-05-09
DK531088D0 (da) 1988-09-23
FI89005B (fi) 1993-04-30
AU2215388A (en) 1989-05-11
IE60311B1 (en) 1994-06-29
FI89005C (fi) 1993-08-10
EP0309157B1 (en) 1991-04-03
GB2209940B (en) 1991-08-14
JPH02270820A (ja) 1990-11-05
IE882709L (en) 1989-03-24

Similar Documents

Publication Publication Date Title
GB2209940B (en) Sustained release etodolac
ES8402155A1 (es) Un metodo para producir formas posologicas unitarias solidas que al administrarse siguen una pauta de liberacion regular y prolongada.
EP0525389A3 (en) Process for preparing mechanically stable, well disintegrating tablets from small active agent containing solid forms
IE831799L (en) Controlled release naproxen and naproxen sodium tablets.
ES8500740A1 (es) Un metodo para la preparacion de una forma posologica unitaria solida, terapeuticamente activa, con pauta de liberacion regular y prolongada al ser administrada.
AU588136B2 (en) Spray dried acetaminophen
ES8303091A1 (es) Un procedimiento para la preparacion de una nueva formulacion de bacampicilina.
KR890009376A (ko) 분무 건조된 이부프로펜
CA2127111A1 (en) A Method for Preparing Enteric-Coated Oral Drugs Containing Acid-Unstable Compounds
IL72291A0 (en) Film-forming compositions for enveloping solid forms,and products coated with said compositions
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
ES8307098A1 (es) Un procedimiento para la preparacion de un nuevo antitrombosico a base de oligosacaridos y polisacaridos.
GR3003887T3 (ko)
ES2008604A6 (es) Procedimiento de preparar aditivos para productos ingeribles y aditivo correspondiente.
ES8502440A1 (es) Procedimiento para preparar acepinoindoles.
EP0285871A3 (en) Sustained release granulate without binding agent
BG60697B2 (en) Medicamentous form having continous release based on ethodolacquer
IE831267L (en) Compostions containing salbutamol

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J121 Written withdrawal of request for trial
J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20080318

Effective date: 20080827

FPAY Annual fee payment

Payment date: 20100630

Year of fee payment: 15

EXPY Expiration of term